PomegraIovance Stock Jumps 31% After 2026 Guidance Raise
Why is Iovance stock up today?
Iovance Biotherapeutics (IOVA) stock jumped 31% to about $14.45 on Tuesday after the company raised its 2026 revenue guidance to $410–420 million, citing strong demand for its Amtagvi cancer therapy.
Key numbers
| 2026 revenue guidance | $410–420Mfrom $350–370M |
|---|---|
| IOVA share move | +31%to about $14.45 on Sep 29 |
| Q2 2026 product revenue | $99.3M+66% vs a year ago |
| Stock move this year | +425%year to date (per [2]) |
| Treatment centers | ~100targeting 110+ by year-end |
| Market value | $6.3Bafter the jump (per [3]) |
What happened
Iovance Biotherapeutics (IOVA) stock jumped 31% to about $14.45 on Tuesday after the company raised its 2026 revenue guidance to $410–420 million, citing strong demand for its Amtagvi cancer therapy. Guidance is a company's own forecast for the year. Iovance had expected $350–370 million, so the middle of the range rose by $55 million. The forecast follows a record second quarter, when product sales of $99.3 million were about 66% higher than a year earlier. The stock is up about 425% this year (per).
Why it matters
Iovance Biotherapeutics is showing that Amtagvi, a melanoma (skin cancer) treatment made from a patient's own immune cells, is selling faster than the company first planned. The new forecast implies sales growth of nearly 60% this year. That matters for a company still losing money: it reported a $47.3 million net loss in the second quarter. Goldman Sachs said early launch problems are starting to ease.
Who this affects
- MarketneutralLow impact
- Mostly a single-stock move; little effect on wider markets.
- CompanybullishHigh impact
- Stronger sales outlook boosts confidence in Amtagvi launch.
- CompetitorsneutralLow impact
- Cell-therapy peers face a stronger rival; effect unclear.
- IndustrybullishMedium impact
- Shows demand for personalized cancer cell therapies is building.
Iovance vs Legend Biotech, Autolus Therapeutics
How we got here
Iovance reports record Q2 product revenue of $99.3M and says it is reviewing guidance
Iovance raises 2026 revenue guidance to $410–420M; shares jump more than 30%
HC Wainwright lifts its price target on Iovance to $20 from $9 (per)
What to watch
- Third-quarter results, including Amtagvi sales compared with the raised full-year forecast2026-11
- Whether treatment centers reach at least 110 by year-end 20262026-12-31
Educational content only. Not investment advice.
More briefsAll briefs →
Hancock Whitney Stock Falls 10% After $3.2B Trustmark Deal
Hancock Whitney (HWC) is paying $3.2B in stock for Trustmark, giving that bank's holders 35% of the new firm
10-Year Treasury Yield Rises to 5.15% on Fed Hike Odds
The 10-year yield (US10Y) is up 30 basis points this week as BofA sees Fed rates peaking at 4.5%–4.75%.
Oil Falls 2.4% This Week as Iran Tensions Linger
Oil (Brent, BZ=F) sits near $95 after last week's 16% drop as Iran's clerics weigh leaving the NPT